Development of a novel ophthalmic biomarker

Novai Ltd is developing a highly sensitive diagnostic tool for ophthalmic diseases allowing very early diagnosis, disease monitoring and patient stratification.

The solution has already demonstrated powerful prognostic capability, accurately predicting the degree of disease progression in a cohort of glaucoma patients in Phase 1 and Phase 2 clinical trials (PMID:32310684), and initial findings were published in 2020\.

This project focuses on the advance of this ophthalmic biomarker with added functionality and a formulation compatible with outpatient delivery, to enable very early diagnosis of sight-threatening diseases, and earlier therapeutic intervention.